Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development platform targeting neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    10-19
Key business